Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel.
Bioorg Med Chem. 2010 Sep 1;18(17):6404-13. doi: 10.1016/j.bmc.2010.07.004. Epub 2010 Jul 8.
We report here on a class of quinazoline molecules that inhibit T cell proliferation. The most potent compound N-p-tolyl-2-(3,4,5-trimethoxyphenyl)quinazolin-4-amine (S101) and its close analogs were found to inhibit the proliferation of T cells from human peripheral blood mononuclear cells (PBMC) and Jurkat cells, with IC(50) in the sub-micromolar range. The inhibitor induced G2 cell cycle arrest but did not inhibit IL-2 secretion. The anti-proliferative effect correlated with inhibition of the tyrosine phosphorylation of SLP-76, a molecular element in the signaling pathway of the T cell receptor (TCR). The inhibitor restrained proliferation of lymphocytes with much higher potency than non-hematopoietic cells. This new class of specific T cell proliferation inhibitors may serve as lead molecules for the development of agents aimed at diseases in which T cell signaling plays a role and agents to induce tolerance to grafted tissues or organs.
我们在此报告了一类能够抑制 T 细胞增殖的喹唑啉类分子。最有效的化合物 N-对甲苯基-2-(3,4,5-三甲氧基苯基)喹唑啉-4-胺(S101)及其类似物被发现能够抑制来自人外周血单核细胞(PBMC)和 Jurkat 细胞的 T 细胞增殖,其 IC50 在亚微摩尔范围内。该抑制剂诱导 G2 细胞周期停滞,但不抑制 IL-2 分泌。抗增殖作用与 SLP-76 的酪氨酸磷酸化抑制相关,SLP-76 是 T 细胞受体(TCR)信号通路中的一个分子元件。抑制剂对淋巴细胞的增殖抑制作用比非造血细胞要强得多。这种新型的特异性 T 细胞增殖抑制剂可能成为开发针对 T 细胞信号转导发挥作用的疾病以及诱导对移植组织或器官耐受的药物的先导分子。